This mini-review explores ataluren therapy for nonsense mutation Duchenne muscular dystrophy (nmDMD), covering clinical guidelines and an implementation model for Sweden. Ataluren delays muscle degeneration, preserves ambulation, and improves pulmonary function in ambulatory nmDMD patients. A proposed centralized expert committee would oversee access and monitoring. Despite high costs, equitable treatment strategies aim to enhance care and outcomes for DMD patients with nonsense mutations.

more